HPV, protein p16 and squamous cell carcinoma of the oral cavity

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):292-299. doi: 10.5507/bp.2019.026. Epub 2019 Jun 17.

Abstract

Background: Squamous cell carcinoma of the oral cavity is generally caused by the long-term impact of known risk factors, e.g. tobacco and alcohol, along with chronic traumatisation. A number of studies now implicate HPV infection in head and neck tumour carcinogenesis but the exact role of HPV infection in the oral cavity remains unclear.

Methods: In this study, we evaluated 78 patients with oral squamous cell carcinoma (OSCC) for the expression of protein p16 in the context of HPV positivity and its influence on the overall survival rate, disease location, staging and grading.

Results: Regarding the tumour location, no significant difference was found between HPV-positive and HPV-negative patients, nor between p16-positive and p16-negative patients. There was also no trend in terms of HPV status and stage, and differentiation of carcinoma. There was no effect on HPV-positive patients relative to the time to progression (P=0.84) and overall survival rate (P=0.78). P16 positivity was not found to have an effect on the overall survival rate of patients (P=0.41) and there was no correlation between p16 positivity relative to the time to progression (P=0.66).

Conclusions: In summary, the data suggest that there is no effect of HPV status on the prognosis of OSCC patients compared to other HNSCC locations.

Keywords: HPV; human papilloma virus; oral cancer; oral squamous cell carcinoma; p16.

MeSH terms

  • Aged
  • Carcinoma, Squamous Cell / diagnosis*
  • Carcinoma, Squamous Cell / physiopathology*
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mouth Neoplasms / diagnosis*
  • Mouth Neoplasms / physiopathology*
  • Papillomavirus Infections / diagnosis*
  • Papillomavirus Infections / physiopathology*
  • Prognosis
  • Survival Rate

Substances

  • Cyclin-Dependent Kinase Inhibitor p16